The short version of counter-ion fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
=== Discontinued === Acolbifene/prasterone (dehydroepiandrosterone/acolbifene; DHEA/acolbifene; prasterone/acolbifene; Femivia) – combination of acolbifene (selective estrogen receptor modulator (SERM)) and prasterone (dehydroepiandrosterone; DHEA) (androgen, other actions) – decreased libido [68] Alprostadil SEPA (prostaglandin E1 SEPA; alprostadil/soft enhancement of percutaneous absorption; Topiglan) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [69] Alprostadil/lidocaine (NM02216; NM100061) – combination of alprostadil (prostaglandin E1 (PGE1) agonist) and lidocaine (sodium channel blocker, local anesthetic) – premature ejaculation [70] Amesergide (LY-237733; LY237733; LY-237,733) – serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist, other actions – erectile dysfunction, premature ejaculation [71] Apomorphine inhalation (VR-004; VR-040; VR-400) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [72] Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction [73] Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction, premature ejaculation [74] BAY-604552 (BAY98-7081; sGC activator) – guanylate cyclase stimulant – erectile dysfunction [75] Bremelanotide (Rekynda; Vyleesi; PT-141) – melanocortin MC4 receptor agonist – erectile dysfunction [76] CP-866087 (CP-866,087) – μ-opioid receptor antagonist – female sexual dysfunction [77] DA-8031 (DA8031) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [78] Dapoxetine (IMD dapoxetine; YHD-1044) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [79] Delequamine (RS-15385; RS-15385197) – α2-adrenergic receptor antagonist – erectile dysfunction [80] Estradiol/testosterone transdermal (testosterone/estradiol transdermal) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [81] GM-1485 (GPI-1485; NIL-A) – immunophilin modulator – erectile dysfunction [82] Heparin/lidocaine/sodium bicarbonate (alkalised lidocaine and heparin formulation; Hep-Lido-A compounded formulation; U-101; URG-101) – combination of heparin (Factor Xa inhibitor, thrombin inhibitor), lidocaine (sodium channel blocker, local anesthetic), and sodium bicarbonate (absorption enhancer) – dyspareunia [83] hMaxi-K gene therapy (pVAX/hSlo; URO-902) – gene transference – erectile dysfunction [84] INO-1001 (INO1001; Pardex) – poly(ADP-ribose) polymerase inhibitor – erectile dysfunction [85] LGD-2941 (LGD2941; LGD122941; LGD-122941) – selective androgen receptor modulator (SARM) – female sexual dysfunction, male sexual dysfunction [86] Melanotan II (MT-II; PT-14) – melanocortin receptor agonist – erectile dysfunction, male sexual dysfunction [87] Milnacipran (Dalcipran; F-2207; Impulsor; Ixel; Joncia; Midacipran; Midalcipran; Savella; TN-912; Toledomin) – serotonin–norepinephrine reuptake inhibitor (SNRI) – vulvodynia [88] Nitroglycerin topical (Anogesic; Cellegesic; Rectiv; Rectogesic) – nitric oxide donor – dyspareunia, vulvodynia [89] NMI-870 – α2-adrenergic receptor antagonist, nitric oxide donor – erectile dysfunction, female sexual dysfunction [90] Oxytocin (oxytocin gel; oxytocin topical; Vagitocin) – oxytocin receptor agonist – atrophic vaginitis [91] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone – premature ejaculation [92] PF-446687 (PF-00446687; PF-446,687) – melanocortin MC4 receptor agonist – sexual function disorders [93] PF-592379 (PF-000592379; PF-592,379) – dopamine D3 receptor agonist – erectile dysfunction [94] Research programme: therapeutics - Re-Pharm (RP-0217; RP0217) – protein phosphatase 2A (PP2A) inhibitor – sexual function disorders [95] [96] RO-0282425 (RO0282425) – melanocortin MC4 receptor agonist – erectile dysfunction [97] RTN-001 (KD-027; SLX-2101; SLx-2101) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [98] SAR-407899 (SAR407899; SAR407899A) – Rho-associated kinase inhibitor – erectile dysfunction [99] Sertraline (Aremis; Besitran; CP-51974; CP-51974-01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [100] Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [101] Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [102] Tadalafil sublingual (APC-8000) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [103] Tadalafil/tamsulosin (CKD-397; tamsulosin/tadalafil) – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [104] Tadalafil/tamsulosin (YBH-1603) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [105] Testosterone topical (ESP-210) – androgen (androgen receptor agonist) – female sexual dysfunction [106] Testosterone transdermal (FemTestosterone TDS) – androgen (androgen receptor agonist) – female sexual dysfunction [107] Testosterone transdermal (Luramist; testosterone MDTS; testosterone transdermal spray) – androgen (androgen receptor agonist) – female sexual dysfunction [108] TEMPE (Topical Eutectic Mixture for Premature Ejaculation) – undefined mechanism of action – premature ejaculation [109] UK-357903 (UK-357,903) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [110] UK-390957 (UK-390,957) – serotonin reuptake inhibitor (SRI) – premature ejaculation [111] UK-447841 (UK-447,841) – neprilysin inhibitor – female sexual dysfunction [112] VML-670 (VML670; CEB-1555) – serotonin 5-HT1A receptor agonist – female sexual dysfunction, male sexual dysfunction [113]
The two substrates of this enzyme are epipregnanolone and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 5β-dihydroprogesterone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3beta-hydroxy-5beta-steroid:NADP+ 3-oxidoreductase. Other names in common use include 3beta-hydroxysteroid 5beta-oxidoreductase, and 3beta-hydroxysteroid 5beta-progesterone oxidoreductase.
==== Conventional recycle processes ==== In early "straight-through" urea plants, reactant recovery (the first step in recycling) was done by letting down the system pressure to atmospheric to let the carbamate decompose back to ammonia and carbon dioxide. Originally, because it was not economic to recompress the ammonia and carbon dioxide for recycle, the ammonia at least would be used for the manufacture of other products such as ammonium nitrate or ammonium sulfate, and the carbon dioxide was usually wasted. Later process schemes made recycling unused ammonia and carbon dioxide practical. This was accomplished by the "total recycle process", developed in the 1940s to 1960s and now called the conventional recycle process. It proceeds by depressurizing the reaction solution in stages (first to 1.8–2.5 MPa (260–360 psi) and then to 0.2–0.5 MPa (29–73 psi)) and passing it at each stage through a steam-heated carbamate decomposer, then recombining the resulting carbon dioxide and ammonia in a falling-film carbamate condenser and pumping the carbamate solution back into the urea reaction vessel.
A2 Corporation set up a new subsidiary and licensee, A2 Australia, to market and produce its product. A2 Australia established new contracts with the dairy farmers who had A1 protein-free herds, promising better payment terms—a week in advance instead of once per month, after shipment. In December, A2 Corporation sold its interests in A2 Australia to Fraser & Neave, a food marketing giant in Asian markets, for about $1.1 million. A2 Corporation had lost about $1.3 million for 2004, the same as it has lost the year before; the sale allowed A2 Corporation to rely on Fraser & Neave to build the Australian and Asian businesses. A2 Corporation focused on recovering from the deaths of its founders organizationally and financially, relied on its New Zealand licensees to develop the New Zealand market, and turned its focus to developing overseas markets. Between 2004 and 2006, A2 Corporation business continued to grow. In response, Dairy Australia (the national association of the Australian dairy industry) and market competitors such as Parmalat have consistently stated that there is no conclusive scientific evidence to suggest A1 proteins are dangerous and have warned that criticism of normal milk is damaging the entire dairy industry.
Sources: en.wikipedia.org
== Interactions == Lithium plasma concentrations are known to be increased with concurrent use of diuretics—especially loop diuretics (such as furosemide) and thiazides—and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Lithium concentrations can also be increased with concurrent use of ACE inhibitors such as captopril, enalapril, and lisinopril. Lithium is primarily cleared from the body through glomerular filtration, but some is then reabsorbed together with sodium through the proximal tubule. Its levels are therefore sensitive to water and electrolyte balance. Diuretics act by lowering water and sodium levels; this causes more reabsorption of lithium in the proximal tubules so that the removal of lithium from the body is less, leading to increased blood levels of lithium. ACE inhibitors have also been shown in a retrospective case-control study to increase lithium concentrations. This is likely due to constriction of the afferent arteriole of the glomerulus, resulting in decreased glomerular filtration rate and clearance. Another possible mechanism is that ACE inhibitors can lead to a decrease in sodium and water. This will increase lithium reabsorption and its concentrations in the body. Some drugs can increase the clearance of lithium from the body, which can result in decreased lithium levels in the blood. These drugs include theophylline, caffeine, and acetazolamide. Additionally, increasing dietary sodium intake may also reduce lithium levels by prompting the kidneys to excrete more lithium.
== Horticultural classification == This follows the classification adopted by V. Matthews in The International Clematis Register and Checklist 2002, except that C. ispahanica, now considered to have been included in error, has been omitted from the list of parent species in Tangutica Group.
== History == In the Standard Model (SM), matter stability is described by assigning a baryon number B=+1 to the proton (lightest baryon), following Hermann Weyl's 1929 proposed conservation principle. Ernst Stueckelberg formally postulated the baryon number (heavy charge at the time) conservation law in 1939. In the 1950s it was realized that limits on proton decay were exceedingly long. The very existence of advanced life forms on Earth implied
== Properties == The human CRHR2 gene contains 12 exons. Three major functional isoforms, alpha (411 amino acids), beta (438 amino acids), and gamma (397 amino acids), encoded by transcripts with alternative first exons, differ only in the N-terminal sequence comprising the signal peptide and part of the extracellular domain (amino acids 18-108 of CRHR2 alpha); the unique N-terminal sequence of each isoform (34 amino acids in CRHR2 alpha; 61 amino acids in Hs CRHR2 beta; 20 amino acids in CRHR2 gamma) is followed by a sequence common to all isoforms (377 amino acids) comprising most of the multi-pass transmembrane domain followed by a cytoplasmic domain of 47 amino acids. CRHR2 beta is expressed in the human brain; CRHR2 alpha predominates in peripheral tissues. The N-terminal signal peptides of corticotropin-releasing hormone receptor 1 and CRHR2 beta are cleaved off in the endoplasmic reticulum to yield the mature receptors. In contrast, CRHR2 alpha contains a unique pseudo signal peptide that is not removed from the mature receptor. In adenylate cyclase activation assays, CRH-related peptides are 10 times more potent at stimulating CRHR2 beta than CRHR2 alpha and CRHR2 gamma, suggesting that the N-terminal sequence is involved in the ligand-receptor interaction.
Negros was originally called Buglas, an old Hiligaynon word thought to mean "cut off", as the island was thought to have been separated from a larger landmass. It was also known as Mamaylan and Panilougon among Cebuano-speaking Visayans. Among its earliest inhabitants were the aboriginal Ata, one of several Negrito Indigenous Peoples dispersed throughout Southeast Asia that possesses a unique culture. The westernmost portions of the island soon fell under the nominal rule of the Kedatuan of Madja-as based on the neighboring islands of Panay and Guimaras, while the eastern coasts were influenced by the Rajahnate of Cebu from the adjacent island of Cebu.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.